Evolution potentielle d'adocia sans prendre en compte l'arbitragUne rapide analyse en cours d'Adocia, sans prendre en compte le résultat potentiel du désaccord avec Eli Lilly. Je ne prends en compte uniquement l'analyse graphique.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.63 USD
−22.88 M USD
2.32 M USD
About ADOCIA
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. Its product pipelines include: Biochaperone Lispro, Combo, M1pram, Glucagon, Gla Glp-1, Glucagon Glp-1 & Cell Therapy. The company was founded by Gérard Soula, Olivier Soula and Rémi Soula on December 16, 2005 and is headquartered in Lyon, France.
Displays a symbol's price movements over previous years to identify recurring trends.